Compare GCT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | ORKA |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2021 | N/A |
| Metric | GCT | ORKA |
|---|---|---|
| Price | $43.80 | $45.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $33.00 | ★ $57.25 |
| AVG Volume (30 Days) | ★ 708.1K | 504.1K |
| Earning Date | 05-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.70 | N/A |
| EPS | ★ 3.59 | N/A |
| Revenue | ★ $1,161,042,000.00 | N/A |
| Revenue This Year | $14.43 | N/A |
| Revenue Next Year | $6.78 | N/A |
| P/E Ratio | $12.46 | ★ N/A |
| Revenue Growth | ★ 64.96 | N/A |
| 52 Week Low | $11.17 | $5.49 |
| 52 Week High | $48.00 | $45.52 |
| Indicator | GCT | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 69.55 |
| Support Level | $37.46 | $26.02 |
| Resistance Level | $44.01 | N/A |
| Average True Range (ATR) | 2.26 | 3.21 |
| MACD | 0.03 | 0.73 |
| Stochastic Oscillator | 73.90 | 89.39 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.